HURA · TuHURA Biosciences, Inc.

On April 2, 2026, TuHURA's Compensation Committee approved 2025 annual performance bonuses and a 5% cost-of-living adjustment to base salaries for key executives Dr. James Bianco and Dan Dearborn, signaling recognition of their contributions amid the recent Kineta integration. These changes result in updated annual base salaries of $605,956 for the CEO and $403,676 for the CFO, with bonuses of $490,536 and $163,393 respectively. Concurrently, the filing updates pro forma financials in Exhibit 99.1, presenting condensed combined operations for 2025 as if the June 30, 2025 Kineta acquisition—via Merger Subs I and II—had occurred on January 1, 2025. TuHURA, as accounting acquirer, issued 2,868,169 common shares at closing (exchange ratio 0.185298 per Kineta share), plus contingent shares and disposed asset rights, supported by a $12.6M private placement of 4,759,309 shares and warrants. Post-merger, TuHURA holds $34.6M in assets including $8.5M cash as of June 30, 2025, and plans to advance Kineta's KVA12123 (TBS-2025) trials alongside synergies with its programs.